Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Literature DB >> 19911111

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

Eric Raymond¹, Sandrine Faivre, Pascal Hammel, Philippe Ruszniewski.

Abstract

Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2009 PMID： 19911111 DOI： 10.1007/s11523-009-0130-0

Source DB: PubMed Journal: Target Oncol ISSN： 1776-2596 Impact factor: 4.493

10 in total

1. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authors: George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Journal: Lancet Date: 2006-10-14 Impact factor: 79.321

Review 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Authors: Sandrine Faivre; Siham Djelloul; Eric Raymond
Journal: Semin Oncol Date: 2006-08 Impact factor: 4.929

3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245

4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors: Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal: J Clin Oncol Date: 2005-11-28 Impact factor: 44.544

5. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

Authors: Kristian Pietras; Douglas Hanahan
Journal: J Clin Oncol Date: 2004-11-22 Impact factor: 44.544

6. Activity of sunitinib in patients with advanced neuroendocrine tumors.

Authors: Matthew H Kulke; Heinz-Josef Lenz; Neal J Meropol; James Posey; David P Ryan; Joel Picus; Emily Bergsland; Keith Stuart; Lesley Tye; Xin Huang; Jim Z Li; Charles M Baum; Charles S Fuchs
Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544

Review 7. Molecular basis for sunitinib efficacy and future clinical development.

Authors: Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal: Nat Rev Drug Discov Date: 2007-09 Impact factor: 84.694

8. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors: James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544

9. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.

Authors: A Couvelard; D O'Toole; H Turley; R Leek; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella
Journal: Br J Cancer Date: 2005-01-17 Impact factor: 7.640

Review 10. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Authors: Nathalie Theou-Anton; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal: Drug Saf Date: 2009 Impact factor: 5.228

10 in total

8 in total

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

1. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Review 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

5. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

6. Activity of sunitinib in patients with advanced neuroendocrine tumors.

Review 7. Molecular basis for sunitinib efficacy and future clinical development.

8. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

9. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.

Review 10. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

1. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

2. Targeting neuroendocrine tumor: mixing standard options with novel therapies.

Review 3. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).

Review 4. Neuroendocrine neoplasms of the gut and pancreas: new insights.

5. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors.

6. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

7. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.

8. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.